Activity provided by the American Epilepsy Society
Release date: February 15, 2021
Expiration date: February 15, 2024

Overview
This self-directed and interactive web-based learning module will utilize case vignettes to enhance the learner's skills in identifying and managing anxiety in children and adults with epilepsy. Each topic will start with a case scenario and ask the learner to respond to questions related to the case and the overall learning topic. Content will include epidemiology, diagnosis, and treatment. This learning activity is relevant to professional practice, as it aims to build knowledge and skills for managing anxiety in epilepsy; there is abundant data indicating that anxiety is underdiagnosed and undertreated in epilepsy. Furthermore, the 2016 AES Q-PULSE showed lower utilization of anxiety screeners for anxiety than depression in epilepsy, and higher need for referrals for anxiety than depression. This module aims to help bridge the management gap by providing practical education to clinicians.

Target Audience
Advanced Practice Providers, Behavioral Health Providers, Clinicians, Fellows/Trainees, Nurses, Pharmacists

Learning Objectives
Describe the impact and prevalence of anxiety in people with epilepsy.
Identify anxiety symptoms in epilepsy using validated screening instruments.
Describe management strategies for anxiety in epilepsy.

Disclosure Policy
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.

Planning Committee, Faculty Reviewers’ Disclosures of Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with an ineligible company. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with ineligible companies have been mitigated. The following individuals contributed to this activity’s content.

Planning Committee and Faculty
Hamada Altalib, DO, MPH - Sunovion Pharmaceuticals, Inc - Grant Contract;  U.S. Department of Defense – Grant Contract; U.S. Department of Affairs - Employment
Madison Berl, PhD
Lisa Clifford, PhD
Jana Jones, PhD;
Ioannis Karakis, MD, PhD, MSc;
Alanna Kessler-Jones, PhD
Heidi Munger Clary, MD, MPH
Aimee Smith, PhD - Global Blood Therapeutics – Grant/Contract
Daniel Weisholtz, MD

CME Reviewer
Elaine Sing-Wah Seto, MD, PhD

American Epilepsy Society Staff Planners
Cristina Graham
Kandice Kidd, MA

Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards of Integrity and Independence in Accredited Continuing Education, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

For more information regarding contact hours, please call American Epilepsy Society 312.883.3800 or education@aesnet.org.

Credit Designation
The American Epilepsy Society designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificate
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.